Form 4: Apellis Pharmaceuticals Director Stephanie O'Brien Reports Stock and Option Transactions
SEC Form 4
Director Stephanie O'Brien reports acquisition of restricted stock units and stock options in Apellis Pharmaceuticals on January 1, 2025.
Summary
- Stephanie O'Brien, a director of Apellis Pharmaceuticals, reported transactions involving the company's securities.
- On January 1, 2025, O'Brien acquired 6,267 shares of common stock through restricted stock units and disposed of 17,705 shares.
- Following these transactions, O'Brien beneficially owns 17,705 shares of common stock.
- O'Brien also acquired options to purchase 11,199 shares of common stock at an exercise price of $31.91, which vest quarterly and expire on December 31, 2032.
Sentiment
Score: 5
Explanation: Neutral sentiment as the filing simply reports transactions without indicating a clear positive or negative outlook. The disposal of shares is balanced by the acquisition of restricted stock units and options.
Positives
- The grant of restricted stock units and options to a director aligns their interests with those of the shareholders.
Negatives
- The disposal of 17,705 shares by the director could be interpreted negatively by the market, although the reason for disposal is not specified.
Risks
- The value of the stock options is dependent on the future performance of Apellis Pharmaceuticals' stock price.
- Continued service as a director is required for the vesting of the restricted stock units and options.
Future Outlook
The director's future holdings are subject to vesting schedules and continued service with the company.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to monitor the actions of those with privileged information.
Comparison to Industry Standards
- Monitoring insider transactions is a common practice in the pharmaceutical industry to gauge management's confidence in the company's prospects.
- Comparing the vesting schedules and option grants to those of peers like Regeneron or Vertex Pharmaceuticals can provide context on the compensation structure at Apellis.
Stakeholder Impact
- Shareholders can use this information to assess the director's alignment with their interests.
- Employees may view the director's transactions as a signal of confidence or concern regarding the company's future.
Key Dates
| Date | Description |
|---|---|
| 01/01/2025 | Date of transaction: Acquisition of restricted stock units and stock options. |
| 01/01/2025 | Date of grant for restricted stock units, vesting on the first anniversary. |
| 01/01/2025 | Date of grant for stock options, vesting quarterly and expiring on December 31, 2032. |
| 12/31/2032 | Expiration date of the stock options. |
| 01/03/2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.